Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study

BACKGROUND: Dexamethasone intravitreal implant (DEX implant) is a biodegradable, sustained-release implant that releases dexamethasone for up to 6 months. We evaluated the efficacy and safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Dugel, Pravin U., Capone, Antonio, Singer, Michael A., Dreyer, Richard F., Dodwell, David G., Roth, Daniel B., Shi, Rui, Walt, John G., Scott, Lanita C., Hollander, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558971/
https://www.ncbi.nlm.nih.gov/pubmed/26337664
http://dx.doi.org/10.1186/s12886-015-0106-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558971/
https://www.ncbi.nlm.nih.gov/pubmed/26337664
http://dx.doi.org/10.1186/s12886-015-0106-z

Ejemplares similares